期刊文献+

球形活性炭对DL-β-氨基异丁酸吸附性能研究 被引量:2

Adsorption of spherical activated carbon against DL-β-aminobutyric acid
下载PDF
导出
摘要 考察自制聚苯乙烯基球形活性炭(PACSS)对尿毒症毒素DL-β-氨基异丁酸(DL-β-AIBA)的吸附性能,以探究其治疗慢性肾病的可能性。测定了4种活性炭对DL-β-AIBA的吸附等温线、吸附动力学曲线及3 h内吸附率。结果表明,DL-β-AIBA在球形活性碳上的吸附行为符合Freundlich吸附等温线,平衡吸附量与比表面积无关,而与孔径范围在0.6~0.8 nm的超微孔容积有较好的线性关系。动力学符合拟二级动力学模型,颗粒内扩散不是唯一的控速步骤。3 h内,4种活性炭对DL-β-AIBA的吸附率可达40%以上(最高52%),是相同条件下商品药用炭的2.3~3倍,表明其在短时间内对DL-β-AIBA具有较强的吸附能力。 The ability of self-prepared polystyrene-based spherical activated carbons( PACSS) to remove DL-β-aminobutyric acid( DL-β-AIBA),a kind of uremic toxin,is investigated to explore possibility of curing chronic renal disease.The adsorption equilibrium,adsorption kinetic curves and 3 h adsorption rates of 4 kinds of activated carbons for DL-β-AIBA are measured.Results reveal that the adsorption action of DL-β-AIBA on PACSSfits Freundlich adsorption isotherm well.The equilibrium adsorption amount of DL-β-AIBA is independent on specific surface area,but has a good linear relationship with the micro pore volume of pore diameter between 0. 6-0. 8 nm.The adsorption kinetics is found to comply with the pseudo-second-order equation,and the internal diffusion is not the only rate-controlling step. Within 3hours,adsorption rates of four kinds of activated carbons against DL-β-AIBA are all higher than 40%( up to 52%),which is 2. 3-3 times that of medical charcoal under the same conditions,illustrating that the spherical activated carbon has a good adsorption capacity for DL-β-AIBA.
出处 《现代化工》 CAS CSCD 北大核心 2017年第7期113-116,共4页 Modern Chemical Industry
基金 国家自然科学基金资助项目(21177038)
关键词 球形活性炭 DL-β-氨基异丁酸 孔结构 吸附性能 spherical activated carbon DL-β-aminobutyric acid pore structure adsorption performance
  • 相关文献

参考文献2

二级参考文献19

  • 1[1]Mikhalovsky SV. emerging technologies in extracorporeal treatment:focus on adsorption. Perfusion, 2003,18(7) :47 - 54
  • 2[2]Vanholder R. Review on uremic toxins: Classification, concentration,and interindividual variability. Kidney International,2003,63(5): 1934- 1943
  • 3[3]James F. Removal of Middle Molecules with Sorbents. Artif Cells Blood Substit Immobil Biotechnol, 2002,30(5- 6):547- 554
  • 4[4]Clark WR. Middle molecules and small- molecular- weight protiens in ESRD: Properties and strategies for their removal. Adv Ren Replace Ther,2003, 10(4) :270 - 278
  • 5[5]Morena MD. Effect of novel adsorbent on cytokine responsiveness to uremic plasma. Kidney Int,2003,63(3):1150-4
  • 6[6]Winchester JF. The next step from high - flux dialysis: application of sorbent technology. Blood Purif, 2002,20(1):81-6
  • 7[7]Vanholder R. Survival of hemodialysis patients uremic toxin removal.Artifi Organ,2003,27 (7) :218 - 23
  • 8[9]Schlaeper C. High clearance continuious renal replacement therapy with a modified dialysis machine. Kidney Int Suppl, 1999,72(56): S20 - 3
  • 9[10]Lesaffer G. Comparative kinetics of the uremic toxin p - cresol versus creatinine in rats with and without renal failure. Kidney Int, 2003, 64(4): 1365 - 73
  • 10[11]Fagugli RM. Behavior of non - protein- bound and protein- bound uremic solutes during daily hemodialysis. Am J Kidney Dis, 2002,40(2) :339 - 47

共引文献48

同被引文献7

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部